- ISIN US74369R1005
- Land Deutschland
Aktuelle Berichte
News Funktionen
Weitere Funktionen
9 November 2012
Proteo Biotech AG
Q3 report 2012
10 August 2012
Proteo Biotech AG
Q2 report 2012
15 Mai 2012
Proteo Biotech AG
Q1 report 2012
28 März 2012
Proteo Biotech AG
Annual Report 2011
7 November 2011
Proteo Biotech AG
Q3 report 2011
4 August 2011
Proteo Biotech AG
Q2 report 2011
16 Mai 2011
Proteo Biotech AG
Q1 report 2011
15 März 2011
Proteo Biotech AG
Annual Report 2010
12 November 2010
Proteo Biotech AG
Q3 report 2010
12 August 2010
Proteo Biotech AG
Q2 report 2010
17 Mai 2010
Proteo Biotech AG
Q1 report 2010
29 März 2010
Proteo Biotech AG
Annual Report 2009
5 November 2009
Proteo Biotech AG
Q3 report 2009
7 August 2009
Proteo Biotech AG
Q2 report 2009
11 Mai 2009
Proteo Biotech AG
Q1 report 2009
22 April 2009
Proteo Biotech AG
Annual Report 2008
3 November 2008
Proteo Biotech AG
Q3 report 2008
3 September 2008
Proteo Biotech AG
Q2 report 2008
21 Mai 2008
Proteo Biotech AG
Q1 report 2008
14 April 2008
Proteo Biotech AG
Annual Report 2007
15 November 2007
Proteo Biotech AG
Q3 report 2007
31 Juli 2007
Proteo Biotech AG
Q2 report 2007
16 Mai 2007
Proteo Biotech AG
Q1 report 2007
3 April 2007
Proteo Biotech AG
Annual Report 2006
14 Dezember 2006
Proteo Biotech AG
Q3 report 2006
30 Juni 2006
Proteo Biotech AG
Q2 report 2006
30 März 2006
Proteo Biotech AG
Q1 report 2006
23 Dezember 2005
Proteo Biotech AG
Annual Report 2005
14 November 2005
Proteo Biotech AG
Q3 report 2005
15 August 2005
Proteo Biotech AG
Q2 report 2005
Aktuelle News
News Funktionen
Weitere Funktionen
10 Januar 2013
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension
11 Dezember 2012
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)
27 Juni 2012
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: Further rationale for Elafin treatment in newborn infants – convincing preclinical evidence in a neonatal pulmonary model
22 Juni 2012
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)
6 Dezember 2011
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: Major advances in the elafin development program for lung diseases – NIH supports research on Elafin with a $10.8 million grant
16 August 2011
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: EMPIRE-Studie schließt erste Koronarbypass-Patienten ein